2.55 USD
+0.08
3.24%
At close Feb 14, 4:00 PM EST
After hours
2.54
-0.01
0.39%
1 day
3.24%
5 days
0.79%
1 month
-24.78%
3 months
-33.25%
6 months
-61.88%
Year to date
-28.17%
1 year
-83.25%
5 years
-99.04%
10 years
-99.04%
 

About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Employees: 582

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

88% more call options, than puts

Call options by funds: $158K | Put options by funds: $84K

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

6.65% less ownership

Funds ownership: 31.19% [Q2] → 24.54% (-6.65%) [Q3]

21% less funds holding

Funds holding: 145 [Q2] → 114 (-31) [Q3]

26% less capital invested

Capital invested by funds: $39.4M [Q2] → $29M (-$10.4M) [Q3]

49% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 37

76% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 38

Research analyst outlook

We haven’t received any recent analyst ratings for ME.

Financial journalist opinion

Based on 5 articles about ME published over the past 30 days

Neutral
GlobeNewsWire
2 weeks ago
23andMe Launches New Genetic Report on Osteoporosis
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants
23andMe Launches New Genetic Report on Osteoporosis
Negative
CNBC
2 weeks ago
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
23andMe is exploring strategic alternatives, looking to raise capital
Neutral
GlobeNewsWire
2 weeks ago
23andMe Special Committee Announces Exploration of Strategic Alternatives
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the Company's assets, licensing of assets, restructuring, or other strategic action.
23andMe Special Committee Announces Exploration of Strategic Alternatives
Neutral
GlobeNewsWire
2 weeks ago
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Neutral
PYMNTS
4 weeks ago
23andMe Reportedly Considers Selling Lemonaid Telehealth Unit
23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation. The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale, per a Friday (Jan. 17) Business Insider report that cited sources familiar with the matter.
23andMe Reportedly Considers Selling Lemonaid Telehealth Unit
Negative
Business Insider
1 month ago
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
Neutral
GlobeNewsWire
1 month ago
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology
23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care 23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology
Negative
CNBC
1 month ago
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Neutral
GlobeNewsWire
2 months ago
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine.
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
Neutral
Seeking Alpha
3 months ago
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe Holding Co. (NASDAQ:ME ) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the 23andMe Fiscal Year 2025 Second Quarter Earnings Call.
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™